References
- American Cancer Society. Chronic lymphocytic leukemia. Available from: www.cancer.org/docroot/CRI/CRI_2_1x.asp? rnav = criov&dt = 62
- Horner MJ, Ries LAG, Krapcho M, . SEER Cancer Statistics Review, 1975-2006. [Based on November 2008 SEER data submission, posted to the SEER web site 2009.] Bethesda, MD: National Cancer Institute. Available from: http://seer.cancer.gov/csr/1975_2006/
- Keating MJ, Chiorazzi N, Messmer B, . Biology and treatment of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2003:153–175.
- Zelenetz AD, Abramson JS, Advani RH, . NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. J Natl Compr Canc Netw 2010;8:288–334.
- Binet JL, Auquier A, Dighiero G, . A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48:198–206.
- Rai KR, Sawitsky A, Cronkite EP, . Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219–234.
- National Cancer Institute. General information about chronic lymphocytic leukemia. Treatment option overview. [Last Modified: 05/18/2010.] Available from: www.cancer.gov/cancertopics/pdq/treatment/CLL/Patient/page4
- Stephens JM, Gramegna P, Laskin B, . Chronic lymphocytic leukemia: economic burden and quality of life. Am J Ther 2005;12:460–466.
- Kasteng F, Sobocki P, Svedman C, . Economic evaluations of leukemia: a review of the literature. Int J Technol Assess Health Care 2007;23:43–53.
- Bureau of Labor Statistics. Series Id CUUR0000SAM. Available from: http://data.bls.gov/timeseries/CUUR0000SAM?output_view = pct_12mths
- Brown ML, Riley GF, Potosky AL, . Obtaining long-term disease specific costs of care: application to Medicare enrollees diagnosed with colorectal cancer. Med Care 1999;37:1249–1259.
- Lin D, Feuer F, Etzioni R, . Estimating medical costs from incomplete follow-up data. Biometrics 1997;53:419–434.
- Young TA. Estimating mean total costs in the presence of censoring: a comparative assessment of methods. Pharmacoeconomics 2005;23:1229–1242.
- Riley GF, Potosky AL, Lubitz JD, . Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 1995;33:828–841.
- Efron B,Tibshirani RJ. An introduction to the bootstrap. New York: Chapman and Hall; 1993.
- Mason JM, Drummond MF, Bosanquet AG, . The DiSC assay. A cost-effective guide to treatment for chronic lymphocytic leukemia? Int J Technol Assess Health Care 1999;15:173–184.
- Weeks JC, Tierney MR, Weinstein MC. Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med 1991;325:81–86.
- Shanafelt TD, Gunderson H, Call TG. Commentary: chronic lymphocytic leukemia—the price of progress. Oncologist 2010;15:601–602.
- Yabroff KR, Warren JL, Brown ML. Costs of cancer care in the USA: a descriptive review. Nat Clin Pract Oncol 2007;4:643–656.
- Hyde C, Wake B, Bryan S, . Fludarabine as secondline therapy for B cell chronic lymphocytic leukaemia: a technology assessment. Health Technol Assess 2002;6:1–89.
- Agency for Healthcare Research and Quality (AHRQ). HCUPnet, Health Care Utilization Project. Available from: http://hcupnet.ahrq.gov/HCUPnet.jsp?Id=B565049F01C4826F&Form=SelALLLISTED&JS=Y&Action =%3E%3ENext%3E%3E&_ALLLISTED=No
- Marchetti M, Barosi G, Liberato LN. Fludarabine for chronic lymphocytic leukemia. N Engl J Med 2001;344:1166–1167.